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Summary
Plasmodium vivax malaria is a debilitat-
ing, sometimes life-threatening, and eco-
nomically repressive disease of many
tropical and temperate countries outside
Africa, and yet it is perceived as rela-
tively benign. The estimated cost of the
global burden of vivax malaria is
US$1,400,000,000–$4,000,000,000 per
year [1], and more people worldwide
live at risk from P. vivax than P. falciparum
[2]. All age groups suffer P. vivax
infections and endure repeated, incapac-
itating febrile attacks, severe anemia, and
respiratory distress, with poor outcomes
in pregnancy and learning impairment in
children also apparent. Similar to other
neglected diseases, P. vivax affects pri-
marily poor people lacking access to
affordable health care, trapping many
in a relentless cycle of poverty because of
loss of adult productivity and depletion
of meager financial reserves [3–5]. Glob-
al malaria elimination programs are
mobilized against P. falciparum,m o s t
likely because of the greater mortality
rates associated with it, and draw re-
sources away from P. vivax even though
vivax malaria is harder to prevent,
diagnose, and treat, and both species
are co-endemic. There is a consensus
among malaria experts that eliminating
P. vivax will prove more technically
challenging than eliminating P. falciparum
[6], and that there exist fewer tools and a
weaker knowledge base from which to
start an effective global elimination
program [7].
Vivax Malaria: Is Biology
Destiny?
A vivax malaria control program will
require early diagnosis combined with
highly efficacious treatment to cure
dormant liver and blood-stage parasites.
In addition, disruption of mosquito bite
transmission is key, preferably through
sustainable community-based vector con-
trol programs and routine use of drugs
that target the mosquito transmission
(‘‘gametocyte’’) stages found in human
blood. However, case detection is inher-
ently more challenging for vivax malaria
due to two of its biological properties.
First, the parasite’s strong preference to
infect the minor population of reticulo-
cytes (immature red blood cells) in the
bloodstream results in significantly lower
parasitemias, necessitating the use of
thick blood smears and greater micro-
scopic skills for proper diagnosis. In
many endemic regions P. vivax is often
overlooked in co-infections with P. falci-
parum, and newly available rapid diag-
nostic tests have sub-optimal sensitivity
for P. vivax [8,9]. A second and more
significant problem stems from invisible
dormant liver stages that can give rise to
multiple periodic ‘‘relapse infections’’ up
to several years after an infectious
mosquito bite. The unpredictable nature
of relapse infections, which can vary
from as short as three weeks for tropical
strains to five years for strains circulating
in temperate climates, further compli-
cates elimination programs since game-
tocytes typically appear at the earliest
onset of clinical symptoms, allowing
transmission of P. vivax before treatment
can be initiated [10].
P. vivax control may become even
more difficult in coming years as there
is increasing prevalence of clinically
defined chloroquine-resistant P. vivax,
for which little monitoring is possible
without in vitro culture or a genetic
marker for resistance [11]. Equally
troublesome are reports that the new
frontline treatment of artemisin combi-
nation therapy has less impact on P. vivax
than on P. falciparum [12]. Although
artemisin combination therapy refracto-
riness may be largely a consequence of
relapse infections from dormant liver
stages, there is currently only one class
of drug (8-aminoquinolines) with known
activity against P. vivax dormant liver
stages. Unfortunately, 8-aminoquinoline
use is limited by contraindications for
pregnancy, infancy, and G6PD deficien-
cy—a relatively common genetic condi-
tion in many malaria endemic countries
for which a point-of-care diagnostic test
is not available. These limitations for
detection, control, and elimination of P.
vivax infections indicate a critical need to
reduce missed or undetected infections
through routine use of gametocidal drugs
and/or a P. vivax transmission-blocking
vaccine. Only two P. vivax vaccines have
reached phase 1 clinical trials (one a
transmission-blocking candidate anti-
gen), compared to 23 P. falciparum
candidate vaccine antigens, of which
several are in phase 2 and one in phase
3 trials [13].
P. vivax develops in mosquitoes in
temperate climates, thus providing a much
broader geographic range of transmission
than P.falciparum,withmore focal,seasonal,
and epidemic-driven transmission. Current
malaria surveillance, control, epidemiolo-
gy, mapping, and modeling approaches do
not accurately address these transmission
patterns. Outside Africa, there is great
diversity in malaria mosquito vectors,
including species that bite humans primar-
ily outside their homes or early in the
evening, limiting the impact of indoor
residual spraying and insecticide-treated
bed nets. Important P. vivax vector species
have not been colonized for laboratory
research. Levels of insecticide resistance are
unknown for most non-African mosquito
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www.plosntds.org 1 June 2011 | Volume 5 | Issue 6 | e1160Table 1. Comparison of the vivax research recommendations of three malaria research and control policy documents.
Description
‘‘Vivax Malaria Research III:
2009 and Beyond’’
Recommendations NIH/NIAID ‘‘Research Agenda for Malaria’’
Roll Back Malaria ‘‘Global
Malaria Action Plan’’
Year 2009 2008 2008
URL http://www.vivaxmalaria.com/
template_meetings.htm
http://www.niaid.nih.gov/topics/Malaria/
Documents/researchagenda.pdf
http://www.rbm.who.int/gmap/
Enabling
technologies
Robust culture systems Develop and characterize an in vitro
culture system
Animal models
Standardized methodologies
Mathematical models
Genomics tools Functional comparison between
malaria species genomes to define
genetic determinants of relapse
Operational research to determine when
and where mass drug administration is
appropriate, and which drugs work best
and minimize resistance
Low-cost, consistently accurate RDT
Quality assurance system for RDTs and
microscopy
New protocols for primaquine and
chloroquine use in areas where resistance
is common
Strong behavioral change communication
program to ensure adherence to
primaquine treatments
Critical biological
knowledge
Hypnozoite biology Hypnozoite mechanisms of
dormancy and activation
Host–vector ecology Identify mosquito vectors and
effective control tools/interventions
Host–parasite interactions Mechanisms of pathogenesis
Cross-species interactions
Intervention impact analysis
Mine genome to identify possible
targets for rational drug design
Develop a new class of anti-malarial
drug with better safety and pharmacodynamic
profile while retaining anti-hypnozoite
and anti-gametocyte activity
More treatments that target vivax malaria
Identify new target antigens as
vaccine candidates
New vaccine that specifically targets P.
vivax alone, or in combination with a P.
falciparum vaccine component; vaccines
that block transmission
Capacity building Networks: regional associations Regional communication or technical
networks to share monitoring data and
best vivax control practices
Networks: regional elimination groups
Networks: regional conferences
Training: vector biology
Training: primate models
Training: public health
Establish facilities to monitor emergence of drug
resistance in endemic countries
Vivax research emphases and recommendations of the 2008 NIH/NIAID ‘‘Research Agenda for Malaria’’ [19] and the Roll Back Malaria ‘‘Global Malaria Action Plan’’ [20]
are shown compared to those of the vivax malaria research community gathered at the ‘‘Vivax Malaria Research III: 2009 and Beyond’’ conference in Panama, May 2009.
P. vivax research and development recommendations are eagerly awaited from the Bill and Melinda Gates Malaria Eradication Research Agenda. RDT, rapid diagnostic
test.
doi:10.1371/journal.pntd.0001160.t001
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chemical markers of resistance are not
defined. The large diversity of anophelines
in Asia and the Americas may also pose
unanticipated challenges for malaria con-
trol, such as rapid adaptation to highly
populated urban settings (e.g., Anopheles
stephensi in India [14]), preference for
particular P. vivax strains (e.g., A. albimanus
versus A. pseudopunctopenis in Mexico [15]),
and zoonotic transmission of primate
malarias to humans (e.g., P. knowlesi trans-
mission in Malaysia [16]).
Scientific Neglect? Research
Funding, Publication, and
Policy
Grant support for P. vivax research is
unstable and meager. Because of the lack
of a continuous in vitro culture system,
research on P. vivax parasites requires
access to infected patients or primates,
primarily through collaboration. By its
nature, such research proceeds more
slowly and is more expensive, logistically
challenging, and less competitive when
pitted against projects using more modern
experimental research methods. The ma-
jor international tropical disease research
sponsors devote a relatively minor portion
of their annual malaria research budgets
to vivax malaria research. The proportion
of the US National Institutes of Health
(NIH) malaria research budget devoted to
P. vivax increased from 3.0% to 5.1% from
financial year 2005 to financial year 2009.
The tenuous nature of NIH research
support for P. vivax is apparent during
the recent five-year period, as only two of
36 grantees were continuously funded. In
contrast, 8.6% of the Wellcome Trust
malaria research grants in 2009 focused on
P. vivax (not including the Southeast Asia
Major Overseas Programme). The World
Health Organization Special Programme
for Research & Training in Tropical
Diseases supported only two P. vivax–
focused grants in the last five years, and
currently has no active vivax projects.
Recently, the NIH funded ten ‘‘Interna-
tional Centers of Excellence for Malaria
Research,’’ which may include a signifi-
cant focus on vivax research [17].
The lack of research support and the
significance of contributions by P. vivax
endemic country scientists are reflected in
publications concerning vivax malaria in
peer-reviewed scientific journals (Table
S1). PubMed retrieval of malaria articles
published between January 1960 and
January 2010 indicates that only 12%
focused on vivax malaria. Approximately
9% of the malaria papers published by first
authors from developed countries con-
cerned P. vivax, compared to 20% of the
papers published by first authors from
developing/endemic countries. Develop-
ing country scientists authored a total of
51% of all the vivax papers published
during this 50-year span. This proportion
likely underrepresents the contribution
from vivax endemic country scientists
because of the lack of inclusion of many
national journals in the PubMed archive.
Malaria research and control policy
documents are increasingly including vi-
vax malaria, usually as a minor focus. The
Disease Control Priorities in Developing
Countries project published a chapter,
‘‘Conquering Malaria,’’ in April 2006
[18], which describes the distribution of
vivax malaria and its threat to pregnancy
but does not consider vivax in the analysis
of morbidity risk, economic impact, im-
plementation of interventions, or research
priorities. The 2008 NIH/National Insti-
tute of Allergy and Infectious Diseases
(NIAID) ‘‘Research Agenda for Malaria’’
[19], which recognized that vivax and
other non-falciparum species ‘‘…exhibit
unique features that may require alterna-
tive interventions and strategies…’’ when
considering global elimination of malaria,
recommended support for specific vivax
malaria activities in four out of nine
priority objectives. Roll Back Malaria’s
‘‘Global Malaria Action Plan’’ [20], also
issued in 2008, and ‘‘Shrinking the
Malaria Map,’’ issued in 2009 by the
Malaria Elimination Group [6], include
more extensive consideration of vivax
malaria in research recommendations, as
well as control strategies directed to
research funders and malaria policy mak-
ers (the vivax research recommendations
of these documents are compared to those
of the vivax malaria research community
gathered at the 2009 conference ‘‘Vivax
Malaria Research III: 2009 and Beyond’’
in Table 1). A recurrent theme in these
documents is the lack of data and
interventions specific for vivax malaria
upon which evidence-based strategies to
tackle vivax malaria can be constructed.
What Can PLoS Neglected
Tropical Diseases Do?
In the world of scientific publishing, PLoS
Neglected Tropical Diseases (PLoS NTDs) was
designed to serve as a clarion for scientific
progress on tropical diseases neglected by
the mainstream journals. P. vivax clearly
meets the journal’s definition of a neglected
tropical disease as defined in the journal’s
scope: ‘‘[Neglected tropical diseases] are a
group of poverty-promoting chronic infec-
tious diseases, which primarily occur in
rural areas and poor urban areas of low-
income and middle-income countries.
They are poverty-promoting because of
their impact on child health and develop-
ment, pregnancy, and worker produc-
tivity…’’ (http://www.plosntds.org/static/
scope.action). P. vivax manuscripts should
be treatedthe sameas all other manuscripts
submitted to PLoS NTDs, and not allocated
to a special category and selected on a case-
by-case basis, as is the current editorial
policy. This additional level of scrutiny may
dissuade endemic country scientists—the
very authors that are particularly encour-
aged to submit their research to PLoS
NTDs—from submitting it. A scientific
publication ‘‘home’’ for reporting vivax
research results at PLoS NTDs, one easily
accessible online, will provide greater
cohesion and information exchange among
the vivax research community, thinly
scattered across the globe, because the
PLoS NTDs editors are known to make
special efforts to encourage publication
from endemic country authors. It is also
hoped that the high profile of PLoS NTDs
will foster greater awareness of the need to
specifically address vivax malaria—and
other non-falciparum species that infect
humans—in the quest to eliminate malaria
world wide.
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